To support patients, BridgeBio will provide Attruby free for life to U.S. clinical trial participants. The company has also ...

We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...

Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...

With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...

Oppenheimer analyst Trevor Allred maintained a Hold rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares opened ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

Kostas Biliouris, an analyst from BMO Capital, maintained the Hold rating on BridgeBio Pharma (BBIO – Research Report). The associated price ...

Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...